Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Safety and Practicality of Breast Conservation Surgery in Large Tumors
- Weekly Topotecan Plus Ziv-Aflibercept in Platinum-Treated Small-Cell Lung Cancer
- Less Frequent Zoledronic Acid an Option in Metastatic Breast Cancer
- Adjuvant Doxorubicin Plus Cyclophosphamide vs Paclitaxel in Breast Cancer
- Adjuvant Exemestane With Ovarian Suppression Reduces Recurrence of Early HR+ Breast Cancer
- Dr. Lee Schwartzberg's 2014 ASCO Abstract Recommendations—Breast Cancer: Cytotoxics, Local Therapy, and Triple-Negative Disease
- Melatonin Use in Breast Cancer Survivors
- Meta-Analysis of Historical Trial Data: What Should We Do With the Information?
- Guideline Update on Sentinel Lymph Node Biopsy for Early-Stage Breast Cancer
- Effect of Radiotherapy After Mastectomy and Axillary Surgery on 10-Year Recurrence and 20-Year Breast Cancer Mortality